New tablet form aims to protect kidneys in transplant patients
NCT ID NCT07267208
Summary
This study is testing whether switching liver transplant patients from a regular entecavir pill to a dissolving tablet version helps protect their kidneys. Researchers want to see if this easier-to-take form maintains protection against hepatitis B virus recurrence while being gentler on kidney function. The study will follow 82 stable transplant patients for 48 weeks to compare results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.